Phase II Open-Label Study of Weekly Taxoprexin (DHA-paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-choroidal Melanoma
Latest Information Update: 08 Jan 2019
Price :
$35 *
At a glance
- Drugs DHA-paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors American Regent; Luitpold Pharmaceuticals
- 14 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Jan 2007 Status changed from recruiting to in progress.